View Press Releases

SeqOnce Biosciences Launches AzureSeq One-Step Universal SARS-CoV-2 RT-qPCR Kit

July 16, 2020

PASADENA, CA - Jul 16, 2020 - SeqOnce Biosciences Launches AzureSeq One-Step Universal SARS-CoV-2 RT-qPCR Kit

SeqOnce Biosciences, Inc., announced today the launch of its new AzureSeq One-Step Universal RT-qPCR kit for the detection of novel coronavirus, SARS-CoV-2. This kit allows for fast turnaround time for customization and delivers a reliable, highly sensitive one-step multiplex RT-qPCR solution for rapid testing.

AzureSeq targets two regions of SARS-CoV-2 virus N nucleocapsid protein gene plus control region of RNaseP gene and is available in two formats: wet and lyophilized. AzureSeq is compatible with CDC recommended RNA extraction kits and qPCR instruments, yielding the daily processing of hundreds of samples using routine instruments. 

“We are excited to join the global fight against COVID-19 by providing a simple, reliable multiplex assay that improves CLIA lab throughput and speed,” stated Chris Angermayer, CEO of SeqOnce. “AzureSeq enables technicians to rapidly turn-around results compared to single-plex protocols.”

“AzureSeq is an excellent platform for a number of short-term future improvements, including lyophilization” commented Joe Dunham, CSO of SeqOnce. “Lyophilization will significantly reduce technician handling to further improve CLIA lab output, while removing the shipping burdens associated with dry ice.”

Chris Angermayer went on the explain “SeqOnce witnessed the need for rapid testing to fight the COVID-19 pandemic and made the decision to expand the business model from NGS to include genomics thus helping our business remain afloat during these difficult times and providing the much-needed support of diagnostic testing.”

AzureSeq “Wet” is EUA-submitted. For prescription use only. For in-vitro diagnostic use only. Only for use under Food and Drug Administration Emergency Use Authorization. AzureSeq “Dry” is currently Research Use Only (RUO).  

About SeqOnce Biosciences, Inc.

SeqOnce Biosciences is a life science company developing innovative products for Next Generation Sequencing (NGS) and technologies that address critical needs in the research and clinical markets. Learn more at